TELA insider award: 11,925 RSUs; option for 17,550 shares at $1.48

Rhea-AI Filing Summary

Reporting person: Betty Jo Rocchio, a director at TELA Bio, Inc. (TELA), reported securities awards received on 10/09/2025 and the filing was signed on 10/10/2025.

The report shows 11,925 restricted stock units (RSUs) granted with zero purchase price; these RSUs vest in three equal annual installments beginning on 10/09/2026, subject to continued service. The filing also reports a stock option to buy 17,550 shares with an exercise price of $1.48, granted on 10/09/2025, vesting monthly over 36 months and expiring on 10/09/2035.

Insights

Corporate Governance Analyst

Director awards align compensation with multi‑year service.

The director received 11,925 RSUs and an option for 17,550 shares, both conditioned on continued service, which supports retention by spreading economic value over 2026–2028 for RSUs and monthly through the next three years for the option.

Key dependencies include continued board service and potential dilution as these awards convert to common stock; monitor vesting milestones and any future option exercises over the next 36 months.

Compensation & Tax Specialist

Structure mixes time‑based RSUs and long‑dated options at a low strike.

The RSUs carry no exercise cost and vest in annual installments starting 10/09/2026, creating taxable events upon vesting. The option has a $1.48 strike and a 10/09/2035 expiration, providing long-term upside if share price rises above the strike before expiration.

Investors should note the potential short‑term dilution when vesting occurs and the timing of taxable events tied to vesting and option exercise over the next 36 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rocchio Betty Jo

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		A		11,925(1)	A	$0	11,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.48	10/09/2025		A		17,550		(2)	10/09/2035	Common Stock	17,550	$0	17,550	D

Explanation of Responses:

1. These restricted stock units will vest in three equal annual installments beginning on October 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date.

2. The option vests in 36 equal monthly installments on each monthly anniversary of October 9, 2025, in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Megan Smeykal, Attorney-in-Fact	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.